Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Wuyts, R. Vos, B. Vanaudenaerde, S. De Vleeschauwer, M. Rinaldi, W. Janssens, M. Demedts, M. Thomeer, E. Verbeken, G. Verleden (Leuven, Belgium). Azithromycin in a bleomycin mouse model: finding the holy grail for pulmonary fibrosis?. Eur Respir J 2009; 34: Suppl. 53, 230

Member's Comments

No comment yet.

Related content which might interest you: Combined pulmonary fibrosis and emphysema: bad and ugly all the same? Source: Eur Respir J, 50 (1) 1700846; 10.1183/13993003.00846-2017 Year: 2017 Prognostic staging of acute pulmonary embolism: are we closer to the holy grail? Source: Eur Respir J 2014; 44: 565-567 Year: 2014 Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard Source: Eur Respir J 2015; 45: 1208-1210 Year: 2015 Treatable traits: a step closer to the “holy grail” of asthma control? Source: Eur Respir J, 55 (3) 2000002; 10.1183/13993003.00002-2020 Year: 2020 Opening Lecture: Is human pulmonary fibrosis simply lung regeneration without a blueprint? Source: ERS Lung Science Conference 2021 Year: 2021 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007 What have we learned from basic science studies on idiopathic pulmonary fibrosis? Source: Eur Respir Rev, 28 (153) 190029; 10.1183/16000617.0029-2019 Year: 2019 Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1218-1220 Year: 2015 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Combined pulmonary fibrosis and emphysema: A distinct entity? Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Late Breaking Abstract - MIF inhibition in a murine model of bleomycin-induced lung fibrosis Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance? Source: Eur Respir J, 55 (6) 2000811; 10.1183/13993003.00811-2020 Year: 2020 Epithelial pIgR: A new player in idiopathic pulmonary fibrosis? Source: International Congress 2018 – New kids on the block: novel molecular pathways and therapeutic targets in chronic lung diseases Year: 2018